Q4 2026 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Fredun Pharmaceuticals Ltd (BOM:539730) reported a strong revenue growth of 27.27% year-on-year for Q4 FY26, with total income reaching INR230 crores.
- The company's EBITDA for Q4 FY26 was INR29.13 crores, reflecting a robust growth and an improved EBITDA margin of 13.67%, expanding by 326 basis points.
- Net profit for the quarter increased by 56.47% year-on-year, reaching INR11.07 crores, with a net profit margin improvement to 5.19%.
- The company is launching new product lines in hormonal and anti-aging sectors, which are expected to tap into fragmented markets with high demand.
- Fredun Pharmaceuticals Ltd (BOM:539730) has a strategic focus on expanding its mobility division, with plans to reach INR100 crores in revenue within two and a half years.
- The geopolitical tensions in the Middle East have led to increased raw material costs, although the company has managed to mitigate immediate impacts through buffer stock.
- The company's working capital requirements remain high, which has been a concern for investors, although improvements have been noted.
- Debt levels are a point of concern, with the company acknowledging the need to manage interest costs and improve financial ratios.
- The transition from a traditional pharmaceutical company to a consumer product company involves risks and requires careful management of resources and market positioning.
- Despite strong growth, the company faces challenges in maintaining sustainable margins as it expands into new markets and product lines.
Ladies and gentlemen, good day and welcome to Q4 FY26 business conference call of Fredun Pharmaceuticals Limited hosted by Kiran Advisors Private Limited.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict.
(Operator Instructions)
Please note that this conference is being recorded. I now hand the conference call over to Ms. Sakhi Panjiyara from Period Advisors. Thank you and over to you ma'am.
Good morning, everyone. Thank you for joining the Q4 FY26 earnings conference call of Cedan Pharmaceuticals Limited. We have today with us Mr. Fredun Medhora, Managing Director of the company. Before handing over to him to address your questions, let me briefly walk you through the company's performance for the quarter and year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
